6.94
-0.17(-2.39%)
Currency In USD
| Previous Close | 7.11 |
| Open | 7.35 |
| Day High | 7.69 |
| Day Low | 6.66 |
| 52-Week High | 11 |
| 52-Week Low | 2.02 |
| Volume | 1.27M |
| Average Volume | 389,921 |
| Market Cap | 837.17M |
| PE | -12.39 |
| EPS | -0.56 |
| Moving Average 50 Days | 6.36 |
| Moving Average 200 Days | 5.76 |
| Change | -0.17 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $138.8 as of June 25, 2025 at a share price of $6.94. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $816.47 as of June 25, 2025 at a share price of $6.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Therapeutics, Inc. Announces Reverse Stock Split
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025LOS ALTOS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
GlobeNewswire Inc.
Jun 10, 2025 10:00 AM GMT
- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therape
Unicycive Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
May 22, 2025 11:00 AM GMT
LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive